[
  {
    "ts": null,
    "headline": "5 Revealing Analyst Questions From Bio-Techne’s Q1 Earnings Call",
    "summary": "Bio-Techne's first quarter results were met with a positive market reaction as the company delivered both organic revenue growth and adjusted profit above Wall Street expectations. Management attributed this momentum to robust demand from large pharmaceutical customers, particularly in its core reagents and protein analysis tools, as well as continued execution on cost control and operational efficiency. CEO Kim Kelderman highlighted the company's ability to manage profitability despite an uncer",
    "url": "https://finnhub.io/api/news?id=5cb04443191bd02f589d975fde1dabb809089b5528282bb72c793e092e0eac04",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752039210,
      "headline": "5 Revealing Analyst Questions From Bio-Techne’s Q1 Earnings Call",
      "id": 135836521,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Bio-Techne's first quarter results were met with a positive market reaction as the company delivered both organic revenue growth and adjusted profit above Wall Street expectations. Management attributed this momentum to robust demand from large pharmaceutical customers, particularly in its core reagents and protein analysis tools, as well as continued execution on cost control and operational efficiency. CEO Kim Kelderman highlighted the company's ability to manage profitability despite an uncer",
      "url": "https://finnhub.io/api/news?id=5cb04443191bd02f589d975fde1dabb809089b5528282bb72c793e092e0eac04"
    }
  }
]